Biotech · Private company
Repurposed Therapeutics, Inc.
Track this companyFree. Adds Repurposed Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials100 recruiting or active
Pipeline programs9From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline9
- DPI-386 Nasal GelPhase 3 · Motion SicknessClinicalTrials.gov · fetched Nov 12, 2026
- ScopolaminePhase 3 · Motion SicknessClinicalTrials.gov · fetched Nov 12, 2026
- scopolamine HBrPhase 3 · Motion SicknessClinicalTrials.gov · fetched Nov 12, 2026
- Scopolamine Nasal GelPhase 3 · Motion SicknessClinicalTrials.gov · fetched Nov 12, 2026
- Transderm Scop®Phase 3 · Motion SicknessClinicalTrials.gov · fetched Nov 12, 2026
- Transdermal ScopolaminePhase 3 · Motion SicknessClinicalTrials.gov · fetched Nov 12, 2026
- DPI-386 Nasal GelPhase 2 · Motion Sickness, SpaceClinicalTrials.gov · fetched Nov 12, 2026
- Other (e.g., promethazine, meclizine)Phase 2 · Motion Sickness, SpaceClinicalTrials.gov · fetched Nov 12, 2026
- ScopolaminePhase 1 · Major Depressive Disorder (MDD)ClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials10
- Efficacy and Safety of DPI-386 Nasal Gel for the Prevention of Nausea and Vomiting Associated With MotionPHASE3 · COMPLETED · started Aug 23, 2022ClinicalTrials.gov NCT05548270 · fetched Nov 12, 2026
- Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor PerformancePHASE2 · UNKNOWN · started Jan 21, 2022ClinicalTrials.gov NCT05886660 · fetched Nov 12, 2026
- Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor PerformancePHASE2 · UNKNOWN · started Aug 10, 2021ClinicalTrials.gov NCT05852730 · fetched Nov 12, 2026
- Nasal Gel for the Prevention of Nausea and Vomiting Associated With MotionPHASE3 · COMPLETED · started Jun 14, 2021ClinicalTrials.gov NCT04947423 · fetched Nov 12, 2026
- Nasal Gel for the Prevention and Treatment of Nausea Associated With Motion SicknessPHASE3 · COMPLETED · started Jun 9, 2019ClinicalTrials.gov NCT04184115 · fetched Nov 12, 2026
- Prevention and Treatment of Nausea Associated With Motion Sickness in Senior SubjectsPHASE3 · COMPLETED · started Jun 7, 2019ClinicalTrials.gov NCT03988530 · fetched Nov 12, 2026
- The Prevention and Treatment of Nausea Associated With Motion SicknessPHASE3 · COMPLETED · started Apr 26, 2019ClinicalTrials.gov NCT03986905 · fetched Nov 12, 2026
- Nasal Gel Under Military Operational Conditions for the Prevention of Nausea Associated With Motion SicknessPHASE3 · UNKNOWN · started Apr 22, 2019ClinicalTrials.gov NCT04272255 · fetched Nov 12, 2026
- Scopolamine in Healthy VolunteersPHASE1 · UNKNOWN · started Aug 1, 2018ClinicalTrials.gov NCT03874130 · fetched Nov 12, 2026
- DPI 386 Nasal Gel for the Prevention of Nausea Associated With Motion SicknessPHASE2_PHASE3 · TERMINATED · started Jun 29, 2018ClinicalTrials.gov NCT04219982 · fetched Nov 12, 2026